ArticleArchives of gynecology and obstetrics2025
Methotrexate plus low-dose prednisolone compared with high-dose corticosteroid therapy in the management of idiopathic granulomatous mastitis.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Idiopathic granulomatous mastitis in the United Arab Emirates: a retrospective case series of clinical features, management, and outcomes.Clinical rheumatology · 2026Article
- An endocrine microbe immunity framework for granulomatous mastitis toward phenotype-oriented interpretation.iScience · 2026Review
- Cystic Neutrophilic Granulomatous Mastitis in Accessory Breast Tissue: A Case Report.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIdiopathic granulomatous mastitis (IGM) is a chronic, relapsing inflammatory breast disease of unknown etiology. Its unpredictable course and unclear pathogenesis have made treatment a persistent clinical challenge. This study aimed to evaluate treatment outcomes in patients with IGM, focusing on extending remission periods and reducing relapse rates after discontinuation of therapy.
methodsThis retrospective cohort study included 200 patients with histopathological confirmed idiopathic granulomatous mastitis who were referred to the Teaching and Therapeutic Center at the Central Hospital of Mazandaran University of Medical Sciences. Patient demographics, pathological characteristics, treatment regimens, remission duration, and recurrence rates were analyzed.
resultsFrom January 2018 to December 2024, a total of 200 patients were enrolled in the study, with a mean age of 33 years (range: 18-54 years) and a mean follow-up duration of 34 months (range: 8-51 months). Patients were divided into two treatment groups: Group A received high-dose prednisolone combined with abscess drainage (n = 99), while Group B received low-dose prednisolone, abscess drainage, and methotrexate (n = 101). Group B demonstrated a significantly shorter treatment duration (11.56 ± 2.15 months) compared to Group A (14.86 ± 3.42 months; P < 0.001). The mean time to follow-up was significantly longer in Group B (35.97 ± 6.96 months) than in Group A (20.00 ± 7.02 months; P < 0.001). The recurrence rate was lower in Group B (4.9%) than in Group A (23.2%), with the difference approaching statistical significance (P = 0.057). In addition, the mean time to relapse in Group B (34.46 ± 6.50 months) was significantly longer than that of Group A (16.96 ± 5.34 months), indicating that patients receiving the combined regimen of low-dose prednisolone, drainage, and methotrexate experienced a more sustained remission period.
conclusionsAccording to the results, the treatment of idiopathic granulomatous mastitis, especially the moderate to severe form of the disease, using combination therapy with low-dose prednisolone and methotrexate can be associated with a reduction in treatment duration, and increase in remission duration, and a reduction in relapse, and drug side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.